

Attorney Docket No. O/1999.475 US


Please add the following subject heading on page 3, line 21:

--Detailed Description of the Invention--In the Claims


Please cancel claims 1-6 without prejudice or disclaimer of the subject matter contained therein.

Please amend the claims as follows:


7. (Amended) A cyclophane compound having formula A



wherein R is




formula B



Attorney Docket No. O/1999.475 US

A¹ cont
wherein X is



or a pharmaceutical acceptable salt thereof.

A²
10. (Amended) The kit according to claim 9, wherein the neuromuscular blocking agent is rocuronium and the chemical chelator is γ -cyclodextrin or a derivative thereof.

11. (Amended) A method for reversal of drug-induced neuromuscular block in a patient, comprising:

parentally administering to said patient an effective amount of a chemical chelator capable of forming a guest-host complex with the drug inducing the neuromuscular block in a patient.

Please add the following claims:

A³
--12. The method according to claim 11, wherein the drug inducing the neuromuscular block in the patient is rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine or suxamethonium.

Attorney Docket No. 0/1999.475 US

A3 cont
13. The method according to claim ~~11~~, wherein the chemical chelator is selected from the group consisting of cyclic oligosaccharides and cyclophanes.

14. The method according to claim ~~11~~, wherein the drug inducing neuromuscular block in a patient is rocuronium and the chemical chelator is γ -cyclodextrin or a derivative thereof.

15. A pharmaceutical composition, comprising:
a chemical chelator capable of reversing a drug-induced neuromuscular block, and
and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition according to claim ~~15~~, wherein the chelator is selected from the group consisting of cyclic oligosaccharides and cyclophanes.


17. The pharmaceutical composition according to claim 16, wherein the cyclic oligosaccharide is a cyclodextrin or a derivative thereof.

18. The pharmaceutical composition according to claim 17, wherein the cyclodextrin is γ -cyclodextrin or a derivative thereof.


Attorney Docket No. O/1999.475 US

A304

19. The pharmaceutical composition according to claim 16,
wherein the cyclophane is represented by formula A




wherein R is



and n is 1-5; or

formula B



wherein X is

